Taking point of care to new heights

Broad access to highly accurate diagnostic testing for infectious diseases in less than 30 minutes

COVID-19 Update

Talis Awarded NIH RADx Contract to Launch Talis One™ System for Point-of-Care COVID-19 Testing and Further Strengthens Financial Position and Leadership Team

Read The Release

How Talis Technology
is Changing Patient Care

Infectious diseases, a global problem

Today, patients are often forced to endure days of waiting for lab results.  As a result, doctors may initiate unnecessary isolation or empirical treatment based on incomplete information. This approach is costly and can be harmful to patients.

The Talis Solution

Our technology will enable doctors to rapidly select optimal treatment for their patients — providing physicians and those they treat with greater peace of mind.

COVID-19 is the first infectious disease that the Talis One System will support. Future infectious disease indications may include assays for other respiratory infections, such as influenza, as well as sexually transmitted infections (STIs) and other infections impacting women’s health.

Learn More

In Development. Not currently available for sale.

The Talis Promise

To the Patient

Faster diagnosis leads to better therapy: Personalized therapies that work from day one help accelerate recovery and minimize side effects.

To the Physician

Faster results, greater confidence: Rapid innovative tests inform better treatment decisions.

To the Hospital

Better care experience that reduces cost and improves outcomes: Optimal personalized treatments reduce the length of stay.

To the Health Care System

Systemic healthcare spend is better managed: Cost-efficient, near-patient testing regardless of the care setting, from physician office to hospital bedside.

News

Uncategorized
November 12, 2020

Talis Expands Executive Team and Closes Additional Financing in Preparation for Commercial Launch of Talis One™ System

MENLO PARK, CALIF. – November 12, 2020 – Talis Biomedical Corporation, a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point of care, today announced…
Uncategorized
July 31, 2020

Talis Awarded NIH RADx Contract to Launch Talis One™ System for Point-of-Care COVID-19 Testing and Further Strengthens Financial Position and Leadership Team

Company awarded $25 million in NIH RADx contract and secures $100 million new financing  Industry leaders appointed to executive team, Board of Directors and Scientific Advisory Board  MENLO PARK, CALIF.…
PR
October 11, 2018

Talis Biomedical Corporation announces expansion of Scientific Advisory Board

Jane Schwebke, M.D., joins the Talis SAB MENLO PARK, Calif., Oct. 11, 2018 /PRNewswire/ -- Talis Biomedical Corporation is pleased to announce the expansion of their Scientific Advisory Board and…
Read More

Our Company

Learn More

Join Our Team

See Opportunities